Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ovarian Cancer Metastatic × aldesleukin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 23 Neoplasm Metastasis 11 Leukemia, Myeloid, Acute 10 Pancreatic Neoplasms 7 Carcinoma, Renal Cell 7 Ovarian Neoplasms 6 Leukemia 6 Kidney Neoplasms 6 Uterine Cervical Neoplasms 5 Stomach Neoplasms 5 Lymphoma 5 Carcinoma, Non-Small-Cell Lung 5 Neuroblastoma 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Colonic Neoplasms 4 Breast Neoplasms 4 Rectal Neoplasms 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Neoplasms 3 Lymphoma, Non-Hodgkin 3 Lymphoma, Mantle-Cell 3 Lymphoma, Follicular 3 Leukemia, Myelomonocytic, Chronic 3 Gastrointestinal Neoplasms 3 Vulvar Neoplasms 2 Vaginal Neoplasms 2 Uveal Melanoma 2 Urinary Bladder Neoplasms 2 Triple Negative Breast Neoplasms 2 Recurrence 2

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡